Development of Platform Technology for Recombinant VLP Vaccine with Modified Viral Surface Protein
Project/Area Number |
17K19652
|
Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
Allocation Type | Multi-year Fund |
Research Field |
General internal medicine and related fields
|
Research Institution | Mie University |
Principal Investigator |
|
Project Period (FY) |
2017-06-30 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 遺伝子組換えワクチン / 新興感染症 / プラットフォーム技術 / PIV2 / 生ワクチン / 非増殖型ウイルスベクター / COVID-19 / SARS-CoV-2 / パラインフルエンザウイルス / エボラウイルス / hPIV2 / 組換えワクチン / エボラウイルスワクチン / VLP / エボラワクチン |
Outline of Final Research Achievements |
We have developed a platform technology to generate recombinant vaccines against various infectious diseases by using non-propagative human parainfluenza virus type 2 vector designated as BC-PIV. First we created a vaccine against Ebola virus GP protein, and named as BC-PIV/EBOV-GP. Immunoelectron microscopy revealed that GP protein is abundantly present on the viral surface (collaboration with Prof. Akira Mizoguchi at Mie University). Immunization of mice with the BC-PIV/EBOV-GP resulted in generation of effective neutralizing antibodies against EBOV-GP-pseudotyped vesicular stomatitis virus (collaboration with Prof. Ayato Takada at Hokkaido University). This technology will become a powerful tool to fulfill unmet medical needs, especially against emerging infectious diseases.
|
Academic Significance and Societal Importance of the Research Achievements |
2019年末、COVID-19と呼ばれる新型肺炎が出現し、翌年瞬く間に全世界に広がった。SARS-CoV-2は世界経済を麻痺させ、多くの人命を奪い、一刻も早いワクチンの開発が望まれている。我々は今回のような新興感染症がいつ出現してもおかしくないと考え、約10年前よりバイオコモ(株)と共同で迅速にワクチンを作製するためのプラットフォーム技術を開発してきた。今回、図らずしもその技術を活かす機会が到来し、SARS-CoV-2の遺伝子配列を入手後、文科省の大臣確認が得られてから遺伝子組換え実験を開始し、1ヵ月で4種の新型コロナウイルスワクチン候補を作出した。最良品を選出し、一刻も早くヒトに応用したい。
|
Report
(4 results)
Research Products
(23 results)
-
-
[Journal Article] Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.2020
Author(s)
Sawaki A, Miyazaki K, Yamaguchi M, Takeuchi T, Kobayashi K, Imai H, Tawara I, Ono R, Nosaka T, Katayama N.
-
Journal Title
Int J Hematol
Volume: 111
Issue: 5
Pages: 686-691
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector2019
Author(s)
Ohtsuka J, Fukumura M, Furuyama W, Wang S, Hara K, Maeda M, Tsurudome M, Miyamoto H, Kaito A, Tsuda N, Kataoka Y, Mizoguchi A, Takada A, Nosaka T.
-
Journal Title
Scientific Reports
Volume: 9
Issue: 1
Pages: 1-9
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
[Journal Article] Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice.2018
Author(s)
Nagatake T, Suzuki H, Hirata S, Matsumoto N, Wada Y, Morimoto S, Nasu A, Shimojou M, Kawano M, Ogami K, Tsujimura Y, Kuroda E, Iijima N, Hosomi K, Ishii KJ, Nosaka T, Yasutomi Y, Kunisawa J.
-
Journal Title
Int Immunol
Volume: 30
Issue: 10
Pages: 471-481
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Restrictive interleukin-10 induction by an innocuous Parainfluenza virus vector ameliorates nasal allergy.2017
Author(s)
Yamanaka K, Nakanishi T, Isono K, Hasegawa C, Inada Y, Mizutani K, Matsushima Y, Okada K, Mabuchi T, Kondo M, Yamagiwa A, Kakeda M, Habe K, Nosaka T, Gabazza EC, Yamazaki H, Mizutani H, Kawano M.
-
Journal Title
J Allergy Clin Immunol
Volume: 139
Issue: 2
Pages: 682-686
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
[Journal Article] MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.2017
Author(s)
Takeuchi, T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, Ono R, Nosaka T, Tanaka K, Katayama N.
-
Journal Title
Cancer
Volume: 123
Issue: 7
Pages: 1166-1173
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Presentation] Gene mutations and sites of involvement in duodenal-type follicular lymphoma.2019
Author(s)
Miyazaki K, Takeuchi T, Yamaguchi M, Asano N, Sawaki A, Imai H, Ono R, Nosaka T, Kobayashi K, Tanaka K, Katayama N.
Organizer
15 ICML-International Conference on Malignant Lymphoma.
Related Report
Int'l Joint Research
-
[Presentation] 十二指腸濾胞性リンパ腫における遺伝子変異と浸潤部位.2019
Author(s)
宮崎 香奈, 竹内 俊文, 山口 素子, 浅野 直子, 澤木 昭彦, 今井 裕, 小埜 良一, 野阪 哲哉, 小林 一彦, 田中 匡介, 片山 直之
Organizer
第81回日本血液学会学術集会
Related Report
-
-
[Presentation] Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice.2018
Author(s)
Nagatake T, Suzuki H, Kawano M, Ogami K, Tsujimura Y, Kuroda E, Iijima N, Hosomo K, Ishii KJ, Yasutomi Y, Kunisawa J, (non-JSI member contributors: Hirata S, Nosaka T).
Organizer
第47回 日本免疫学会
Related Report
-
[Presentation] Organogenesis of inducible bronchus-associated lymphoid tissue plays an essential role in Ag85B-hPIV2-based anti-tuberculosis respiratory vaccine in mice.2018
Author(s)
Nagatake T, Suzuki H, Nasu A, Hirata S, Wada Y, Matsumoto N, Shimojou M, Morimoto S, Hosomi K, Ogami K, Tsujimura Y, Kawano M, Nosaka T, Yasutomi Y, Kunisawa J.
Organizer
第11回次世代アジュバント研究会
Related Report
-
-
-
-
-
-
-